Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records
2023
Bertrand, Julie | Barrail-Tran, Aurélie | Fayette, Lucie | Savic, Rada M. | Goujard, Cécile D.Sign©cile | Teicher, Elina | Barau, Caroline | Pruvost, A. G. | Taburet, Anne Marie | Mentré, France | Verstuyft, Céline | Brunet, Aurélie | Commoy, Marie Josèphe | Couffin-Cadiergues, Sandrine | Descamps, Diáne | Duval, Xavier | Le Guellec, Chantal Barin | Nembot, Georges | Panhard, Xavière | Savic, R. | Vrijens, Bernard C. | Cohortes épidémiologiques en population | Université de Versailles Saint-Quentin-en-Yvelines -Institut National de la Santé et de la Recherche Médicale -Université Paris-Saclay-Université Paris Cité | Infection, Anti-microbiens, Modélisation, Evolution | Institut National de la Santé et de la Recherche Médicale -Université Paris Cité -Université Sorbonne Paris Nord | Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes | Commissariat à l'énergie atomique et aux énergies alternatives -Institut National de la Santé et de la Recherche Médicale -Université Paris-Saclay | Centre de recherche en épidémiologie et santé des populations | Université de Versailles Saint-Quentin-en-Yvelines -Assistance publique - Hôpitaux de Paris -Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale -Université Paris-Saclay | Hôpital Bicêtre | Assistance publique - Hôpitaux de Paris | Hôpital Henri Mondor | Assistance publique - Hôpitaux de Paris -Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris | Médicaments et Technologies pour la Santé | Université Paris-Saclay-Institut des Sciences du Vivant Frédéric JOLIOT | Commissariat à l'énergie atomique et aux énergies alternatives -Commissariat à l'énergie atomique et aux énergies alternatives -Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement | Agence Nationale de Recherches sur le Sida et les Hépatites Virales, ANRS
International audience
Show more [+] Less [-]English. Tenofovir (TFV) and emtricitabine (FTC) are part of the recommended highly active antiretroviral therapy (ART). Both molecules show a large interindividual pharmacokinetic (PK) variability. Here, we modeled the concentrations of plasma TFV and FTC and their intracellular metabolites (TFV diphosphate [TFV-DP] and FTC triphosphate [FTC-TP]) collected after 4 and 24 weeks of treatment in 34 patients from the ANRS 134-COPHAR 3 trial. These patients received daily (QD) atazanavir (300 mg), ritonavir (100 mg), and a fixed-dose combination of coformulated TFV disoproxil fumarate (300 mg) and FTC (200 mg). Dosing history was collected using a medication event monitoring system. A three-compartment model with absorption delay (Tlag) was selected to describe the PK of, respectively, TFV/TFV-DP and FTC/FTC-TP. TFV and FTC apparent clearances, 114 L/h (relative standard error [RSE] = 8%) and 18.1 L/h (RSE = 5%), respectively, were found to decrease with age. However, no significant association was found with the polymorphisms ABCC2 rs717620, ABCC4 rs1751034, and ABCB1 rs1045642. The model allows prediction of TFV-DP and FTC-TP concentrations at steady state with alternative regimens. Copyright
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by National Institute for Agricultural Research